{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:40:21Z","timestamp":1788273621475,"version":"build-2803163510"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Alcohol-related liver disease (ALD) is the leading indication for liver transplant in the US; however, use of medications for alcohol use disorder (MAUDs) remains very low overall. Few studies have examined the use of MAUDs for patients with severe ALD, and lack of clinical knowledge around the benefits of MAUDs for severe ALD remains a barrier to their use.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the association between use of MAUDs and mortality among patients with severe ALD referred for liver transplant.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective single-center cohort study was conducted at a tertiary referral center among 1309 patients with severe ALD referred for liver transplant between January 1, 2016, and December 31, 2022. Statistical analysis was performed from January 2023 to December 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Use of MAUDs, including US Food and Drug Administration\u2013approved and off-label treatments.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome was all-cause mortality, as determined by clinical staff and documented in the electronic medical record.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study included 1309 patients (mean [SD] age, 57.1 [10.5] years; 989 men [75.6%]) and had a mean (SD) of 38 (25) months of follow-up. Use of MAUDs for at least 3 months was associated with 6.6% higher 1-year survival (SE, 0.02%) and 18.5% higher 3-year survival (SE, 0.03%). This association persisted in propensity score\u2013adjusted multivariable Cox proportional hazards regression models, independent of Model for End-Stage Liver Disease score, liver transplant status, and other clinical factors (hazard ratio, 0.59; 95% CI, 0.39-0.92).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, use of MAUDs was associated with improved survival among patients with severe ALD. This finding highlights the need for improved access to MAUDs among patients with severe ALD.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.59016","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:30:30Z","timestamp":1770827430000},"page":"e2559016","source":"Crossref","is-referenced-by-count":1,"title":["Medications for Alcohol Use Disorder Among Patients With Severe Alcohol-Related Liver Disease"],"prefix":"10.1001","volume":"9","author":[{"given":"Ram","family":"Sundaresh","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California, Los Angeles"},{"name":"Department of Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasleen","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, Los Angeles"},{"name":"Department of Surgery, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Meza","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy","family":"Saab","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, Los Angeles"},{"name":"Department of Surgery, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Shetty","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, Los Angeles"},{"name":"Department of Surgery, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"1","key":"zoi251567r1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.7326\/ANNALS-24-02157","article-title":"Trends in alcohol use after the COVID-19 pandemic: a national cross-sectional study.","volume":"178","author":"Ayyala-Somayajula","year":"2025","journal-title":"Ann Intern Med"},{"issue":"9","key":"zoi251567r2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1001\/jamapsychiatry.2017.2161","article-title":"Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions.","volume":"74","author":"Grant","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"zoi251567r4","doi-asserted-by":"publisher","first-page":"k2817","DOI":"10.1136\/bmj.k2817","article-title":"Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study.","volume":"362","author":"Tapper","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"zoi251567r5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.14309\/ajg.0000000000000380","article-title":"Alcoholic liver disease epidemiology in the United States: a retrospective analysis of 3 US databases.","volume":"115","author":"Dang","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"zoi251567r6","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.dld.2022.07.007","article-title":"COVID-19 and alcohol associated liver disease.","volume":"54","author":"Deutsch-Link","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"2","key":"zoi251567r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20294","article-title":"Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019.","volume":"3","author":"Wong","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi251567r8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence: a controlled study.","volume":"49","author":"O\u2019Malley","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"13","key":"zoi251567r9","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"issue":"11","key":"zoi251567r10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence.","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"zoi251567r11","first-page":"239","article-title":"Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol.","volume":"30","author":"Paille","year":"1995","journal-title":"Alcohol Alcohol"},{"key":"zoi251567r12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1192\/bjp.171.1.73","article-title":"Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study.","volume":"171","author":"Pelc","year":"1997","journal-title":"Br J Psychiatry"},{"issue":"5","key":"zoi251567r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.13014","article-title":"Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder.","volume":"5","author":"Vannier","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi251567r14","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000093","article-title":"Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis.","volume":"7","author":"Rabiee","year":"2023","journal-title":"Hepatol Commun"},{"issue":"2","key":"zoi251567r16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/acer.13944","article-title":"Gender disparities in alcohol use disorder treatment among privately insured patients with alcohol-associated cirrhosis.","volume":"43","author":"Mellinger","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"issue":"6","key":"zoi251567r17","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1002\/hep.31042","article-title":"Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis.","volume":"71","author":"Rogal","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"zoi251567r18","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.cld.2024.06.012","article-title":"Barriers to alcohol use disorder treatment in patients with alcohol-associated liver disease.","volume":"28","author":"L\u00e9k\u00f3","year":"2024","journal-title":"Clin Liver Dis"},{"issue":"12","key":"zoi251567r19","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1176\/ps.2009.60.12.1618","article-title":"Perceived need for treatment for alcohol use disorders: results from two national surveys.","volume":"60","author":"Edlund","year":"2009","journal-title":"Psychiatr Serv"},{"issue":"11","key":"zoi251567r20","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1176\/appi.ps.201400160","article-title":"Perceived barriers to treatment for alcohol problems: a latent class analysis.","volume":"66","author":"Schuler","year":"2015","journal-title":"Psychiatr Serv"},{"key":"zoi251567r21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jsat.2018.05.003","article-title":"Misconceptions, preferences and barriers to alcohol use disorder treatment in alcohol-related cirrhosis.","volume":"91","author":"Mellinger","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"zoi251567r22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi251567r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.3387","article-title":"Outcomes after initiation of medications for alcohol use disorder at hospital discharge.","volume":"7","author":"Bernstein","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"17","key":"zoi251567r24","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis.","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"zoi251567r25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1055\/a-2717-3496","article-title":"Integrated alcohol use disorder and liver disease management.","volume":"45","author":"Blaney","year":"2025","journal-title":"Semin Liver Dis"},{"key":"zoi251567r3","unstructured":"Key substance use and mental health indicators in the United States: results from the 2021 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration. 2021. Accessed November 30, 2024. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt39443\/2021NSDUHFFRRev010323.pdf"},{"key":"zoi251567r15","unstructured":"Section 5 PE tables\u2014results from the 2023 National Survey on Drug Use and Health: detailed tables, SAMHSA, CBHSQ. Substance Abuse and Mental Health Services Administration. Accessed November 30, 2024. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt47100\/NSDUHDetailedTabs2023\/NSDUHDetailedTabs2023\/2023-nsduh-detailed-tables-sect5pe.htm"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2844921\/sundaresh_2026_oi_251567_1770231762.96816.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:30:32Z","timestamp":1770827432000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2844921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.59016","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]}}}